Last reviewed · How we verify
ABSK021
ABSK021 is a small molecule targeting the PI3K/AKT/mTOR pathway.
ABSK021 is a small molecule targeting the PI3K/AKT/mTOR pathway. Used for Metastatic non-small cell lung cancer, Metastatic breast cancer.
At a glance
| Generic name | ABSK021 |
|---|---|
| Sponsor | Abbisko Therapeutics Co, Ltd |
| Drug class | PI3K/AKT/mTOR pathway inhibitor |
| Target | PI3K/AKT/mTOR pathway |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
ABSK021 acts as a selective inhibitor of the PI3K/AKT/mTOR pathway, which is involved in cell proliferation and survival. This mechanism is relevant for treating various types of cancer.
Approved indications
- Metastatic non-small cell lung cancer
- Metastatic breast cancer
Common side effects
- Diarrhea
- Fatigue
- Nausea
Key clinical trials
- A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor (PHASE1)
- Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER) (PHASE3)
- A Clinical Trial to Evaluate a High-Fat Meal and Omeprazole Enteric-coated Tablets on ASBK021 (PHASE1)
- A Mass Balance Study of [14C]ABSK021 (PHASE1)
- A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD) (PHASE2)
- A Clinical Trial to Evaluate the Effect of Itraconazole and Rifampicin on ABSK021 (PHASE1)
- ABSK021 Food Effect Study in Healthy Subjects (PHASE1)
- A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABSK021 CI brief — competitive landscape report
- ABSK021 updates RSS · CI watch RSS
- Abbisko Therapeutics Co, Ltd portfolio CI